RecruitingNot Applicable

Association of TNFAIP3 With Immune-mediated TTP

Italy400 participantsStarted 2025-04-07

Plain-language summary

This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Patients: Inclusion Criteria: * Diagnosis of iTTP * Above 12 years of age * Caucasian, Italian origin * Written informed consent to participate in the study Exclusion Criteria: * Patients who do not meet the above-listed criteria will be excluded from participation in the study. Controls will be healthy Italian volunteers of Caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.

What they're measuring

Allele frequency of TNFAIP3 variants in cases vs controls

Timeframe: Baseline

Trial details

NCT IDNCT06928233

SponsorFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04

Contact for this trial

Ilaria Mancini, PhD

+390255035414 ilaria.mancini@guest.unimi.it

View on ClinicalTrials.gov More Thrombotic Thrombocytopenic Purpura, Acquired trials